SyntheticMR has shared the results of a newly published multicentre clinical study in the American Journal of Neuroradiology (AJNR) demonstrating the diagnostic equivalence—and potential advantages—of its SyMRI using the ‘3D-QALAS’ method compared to conventional 3D magnetic resonance imaging (MRI) in routine clinical neuroimaging.
The study evaluated a large and diverse patient population across multiple imaging centres, with findings confirming that 3D synthetic MRI using the company’s SyMRI technology matched conventional MRI in terms of sensitivity, specificity, and diagnostic accuracy. Notably, SyMRI received even higher ratings for image quality, according to a recent press release from the company.
“These results underscore the value of SyMRI in real-world clinical practice,” said Johanna Norén, acting chief executive officer (CEO) of SyntheticMR. “With diagnostic performance on par with conventional imaging—and with added benefits in workflow efficiency and quantitative imaging—SyMRI has the potential to enhance diagnostic confidence while streamlining MRI protocols.”
The study in question highlights SyMRI’s ability, particularly in 3D, to deliver quantitative, multi-contrast images in a single, fast scan without compromising image quality, making it a “strong candidate” for advancing scalable and standardised neuroimaging practices, the company further claims.
